Actively Recruiting
Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression
Led by Robert Olson · Updated on 2026-03-11
598
Participants Needed
13
Research Sites
528 weeks
Total Duration
On this page
Sponsors
R
Robert Olson
Lead Sponsor
L
London Regional Cancer Program, Canada
Collaborating Sponsor
AI-Summary
What this Trial Is About
Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques, while trying to avoid healthy tissues and organs. However, SABR treatment requires increased planning, treatment time, cost and potential for higher toxicity due to the higher dose. The purpose of this study is to compare single fraction (SF) SABR vs. multiple fraction (MF) SABR in regards to toxicities, progression-free survival, quality of life (QoL), and cost-effectiveness. In a subset of patients, we will also compare patient QoL, hospitalization rates, and cost-effectiveness between patients who complete QoL questionnaires, record symptoms and receive healthcare provider-guided intervention vs. patients who complete QoL questionnaires only.
CONDITIONS
Official Title
Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 1-5 current oligometastatic or oligo-progressive lesions
- Age 18 years or older
- Able to provide informed consent
- Able to complete electronic patient-reported outcomes and questionnaires independently or with assistance
- Life expectancy greater than 6 months
- Histologically confirmed cancer with metastatic disease seen on imaging
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Controlled primary tumor for at least 3 months with no progression
- History and physical exam including ECOG within 6 weeks before enrollment
- CT chest, abdomen, pelvis or PET-CT within 10 weeks before enrollment and 13 weeks before treatment
- Bone scan within 10 weeks before enrollment and 13 weeks before treatment if no PET-CT
- Brain imaging if primary cancer risks CNS metastases within 10 weeks before enrollment and 13 weeks before treatment
- MRI spine imaging within 10 weeks before enrollment and 13 weeks before treatment for known spine metastases
- FDG PET scan or CT and bone scan within 10 weeks before enrollment and 13 weeks before treatment if solitary lung nodule biopsy unsuccessful
- FDG PET scan within 10 weeks before enrollment and 13 weeks before treatment if colorectal primary with rising CEA but unclear imaging
- Ability to maintain stable position during therapy
- Ability to tolerate immobilization devices for SABR
- Negative pregnancy test within 4 weeks of radiation start for people of child-bearing potential
You will not qualify if you...
- Uncontrolled active cancer besides study indication
- Lesion in femoral bone needing surgical fixation
- Chemotherapy use within 1 week before radiation until 1 week after last fraction
- Serious medical conditions preventing radiotherapy including interstitial lung disease, Crohn's disease with GI radiation, lupus, scleroderma
- Significant overlap with previously treated radiation area exceeding dose limits
- Current malignant pleural effusion
- Liver metastases in the defined "Biliary no fly zone"
- Inability to treat all metastatic or progressing sites
- Brain metastases as the only disease site
- Lesions larger than 5 cm outside the brain except certain bone metastases deemed safe
- Brain metastases larger than 3.5 cm or total brain metastases volume over 30 cc
- Evidence of spinal cord compression unless surgically treated
- Spine instability score greater than 12
- Dominant brain metastasis needing surgery
- Surgical removal of all metastases so no lesion remains for SABR
- Complete response to systemic therapy with no visible disease
- Pregnant or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
BC Cancer
Kelowna, British Columbia, Canada
Actively Recruiting
2
BC Cancer
Prince George, British Columbia, Canada, V2M 7E9
Actively Recruiting
3
BC Cancer
Surrey, British Columbia, Canada
Actively Recruiting
4
BC Cancer
Vancouver, British Columbia, Canada
Actively Recruiting
5
BC Cancer - Victoria
Victoria, British Columbia, Canada
Not Yet Recruiting
6
Princess Margaret Cancer Centre | University Health Network
Toronto, Ontario, Canada, M5G 1X6
Actively Recruiting
7
University Hospital Galway
Galway, Connacht, Ireland, H91 YR71
Actively Recruiting
8
St. Luke's Radiation Oncology Network
Dublin, Dublin, Ireland, D06 E1C9
Actively Recruiting
9
Mater Private Hospital
Dublin, Leinster, Ireland, D07 WKW8
Actively Recruiting
10
Beacon Hospital
Dublin, Leinster, Ireland, D18 AK68
Actively Recruiting
11
Cork University Hospital
Cork, Munster, Ireland, T12 DC4A
Actively Recruiting
12
Bon Secours Radiotherapy Cork in Partnership with UPMC Hillman Cancer Centre
Cork, Munster, Ireland, T12 DV56
Actively Recruiting
13
UPMC Whitfield Hospital - Waterford
Waterford, Munster, Ireland, X91 DH9W
Actively Recruiting
Research Team
R
Robert Olson, MD, MSC, FRCPC
CONTACT
J
Jordanna Laing, MSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here